Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-30 @ 3:23 AM
Study NCT ID:
NCT07467161
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-13
First Post:
2026-03-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Relationship Between Insulin Resistance and Vitamin D in Type 2 Diabetes Mellitus (DM)
Sponsor:
Assiut University
Organization:
Study Overview
Official Title:
Impact of Vitamin D Deficiency on Insulin Resistance Assessed by Triglyceride Glucose Index in Type 2 Diabetic Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2026-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DM
Brief Summary:
The primary aim of the study is to evaluate the association between vitamin D levels and triglyceride-glucose index as a marker of insulin resistance in patients with type 2 DM.
Detailed Description:
All eligible patients will be asked to participate in the study after counseling and written consent. The following data will be collected.
I) Demographic \& baseline data of the participants:
* Gender, age, residence (rural or urban), weight and height.
* Smoking or alcohol consumption.
II) Medical History of the participants:
* Regarding Type 2 DM: onset of diagnosis, current medications, dosage of medications, adherence to treatment, complications of DM.
* Other medical disorders: hypertension, thyroid disease.
III) Clinical and laboratory assessment of the participants:
* Vital signs: Pulse, blood pressure (systolic \& diastolic), temperature and respiratory rate.
* Body mass index (BMI): calculated as weight in kilograms divided by the square of height in meters (kg/ m²).
* Waist circumference of the participants.
* All participants will be fasting overnight (12 hours), and the blood samples will be drawn in the next morning. All blood biomarkers will be tested in the same laboratory. We will measure the following: Fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), 25-hydroxyvitamin D, albumin, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen (BUN), creatinine (S.cr) and uric acid (UA).
* The serum concentration of 25(OH)D will be measured using electro-chemi-luminescence immunoassay.
* Triglyceride-glucose index (TyG) will be calculated as (fasting triglyceride (mg/dL) x fasting glucose (mg/dL)/2).
* Vitamin D deficiency (VDD) is defined as plasma 25(OH)D \< 20 ng/mL; values 20-30 ng/mL are considered insufficiency; and values \> 30 ng/mL are considered sufficiency.
* For those with vitamin D deficiency (25(OH)D \< 20 ng/mL); vitamin D supplementation will be added for correction.
* Follow up of the participants after 3 months: vitamin D level (25-hydroxyvitamin D), Triglyceride-glucose index (TyG), waist circumference and glycemic control reflected by glycosylated hemoglobin (HbA1c).
I) Demographic \& baseline data of the participants:
* Gender, age, residence (rural or urban), weight and height.
* Smoking or alcohol consumption.
II) Medical History of the participants:
* Regarding Type 2 DM: onset of diagnosis, current medications, dosage of medications, adherence to treatment, complications of DM.
* Other medical disorders: hypertension, thyroid disease.
III) Clinical and laboratory assessment of the participants:
* Vital signs: Pulse, blood pressure (systolic \& diastolic), temperature and respiratory rate.
* Body mass index (BMI): calculated as weight in kilograms divided by the square of height in meters (kg/ m²).
* Waist circumference of the participants.
* All participants will be fasting overnight (12 hours), and the blood samples will be drawn in the next morning. All blood biomarkers will be tested in the same laboratory. We will measure the following: Fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), 25-hydroxyvitamin D, albumin, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen (BUN), creatinine (S.cr) and uric acid (UA).
* The serum concentration of 25(OH)D will be measured using electro-chemi-luminescence immunoassay.
* Triglyceride-glucose index (TyG) will be calculated as (fasting triglyceride (mg/dL) x fasting glucose (mg/dL)/2).
* Vitamin D deficiency (VDD) is defined as plasma 25(OH)D \< 20 ng/mL; values 20-30 ng/mL are considered insufficiency; and values \> 30 ng/mL are considered sufficiency.
* For those with vitamin D deficiency (25(OH)D \< 20 ng/mL); vitamin D supplementation will be added for correction.
* Follow up of the participants after 3 months: vitamin D level (25-hydroxyvitamin D), Triglyceride-glucose index (TyG), waist circumference and glycemic control reflected by glycosylated hemoglobin (HbA1c).
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: